fbpx
Coronavirus

AstraZeneca’s COVID-19 Vaccine Data is Being Questioned Over Concerns of ‘Outdated Information’

A safety board overseeing AstraZeneca’s COVID-19 vaccine trial is raising concerns about the company’s data. In an unusual post-midnight statement, the National Institute of Allergy and Infectious Diseases said the Data and Safety Monitoring Board, which monitors the trial, is concerned that “outdated information” may have been included in the trial results.

If the pharmaceutical company did include outdated information from that trial, that could provide an “incomplete view of the efficacy data,” the NIAID said.

The Data and Safety Monitoring Board, an independent group within the agency responsible for reviewing clinical studies, also notified other federal health agencies and AstraZeneca directly of its concerns.

Later Tuesday, AstraZeneca released a statement saying that its interim analysis was based on data with a “cut off” of Feb. 17 and that it had “reviewed the preliminary assessment of the primary analysis and the results were consistent with the interim analysis.” The company said it expected to release the results of its primary analysis within 48 hours.

Read the source article at npr.org

Leave a Review or Comment

Back to top button